Mirati Shares Fall On New Data For Lung Cancer Drug Combo | Enterpreneurship

0
Want create site? Find Free WordPress Themes and plugins.

Want create site? Find Free WordPress Themes and plugins.

of San Diego-based Therapeutics fell 15 percent Monday as from an ongoing mid-stage study of one of its experimental drugs disappointed investors.

Mirati (NASDAQ: MRTX) is one of several biotech companies trying to get in on the mix-and-match cancer immunotherapy game. Drugmakers have been combining immunotherapies with other medicines hoping to help more patients respond, and that has led to a slew of deals and alliances to test various regimens in clinical trials. Results so far have been mixed.

Mirati, for instance, has been testing sitravatinib (MGCD516) in combination with nivolumab (Opdivo), an immunotherapy from… Read more »


UNDERWRITERS AND PARTNERS


Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.